The Polish biotechnology holding Orphinic Scientific is planning a debut on the US stock exchange Nasdaq - informs Filary Biznesu. The move to the US is to take place through a merger with the portfolio company Vasa Therapeutics.
- Our path to New York should be completed in less than two years. For now, we are conducting another round of financing in Poland, worth approximately PLN 40 million. The next steps are the implementation of the pre-IPO in the US in the range of USD 20-40 million and the IPO itself worth approximately USD 50 million - says Adam Kruszewski, CEO of Orphinic Scientific.
